S2G Ventures, a multi-stage venture fund investing in food and agriculture, Bold Capital Partners, an early stage venture investing in life sciences, healthcare and frontier tech, Viking Global Investors, an American-based hedge fund, and GG 1978 SICAF SIF SA, a closed-ended investment fund focusing on pharmaceuticals and biotechnologies, led a $15m Series B round in Solarea Bio, a clinical stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to aid human health. "We are very excited to see the rapid progression from our founding hypothesis: that microbes from fresh fruits and vegetables have health benefits, to the clinical validation stage, and the upcoming commercial launches. I thank our amazing team for their hard work and dedication to execute on our lofty goals. A big part of the company's success has been the role our outstanding investors played partnering with a great team at Solarea, and we are looking forward to continuing successes as we transition to a commercial stage by launching our medical food products to the market." Gerardo V Toledo, Solarea Bio CEO and co-founder.